Metraipolis › archive › dc_5d62113eda2d

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study — Europe PMC PMID:42118670

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42118670
DOI
10.1002/cncr.70457
License (as archived)
solo-consultazione
Archived
2026-11-02T23:30:57.856Z
SHA-256 of the archived text
d772420c84f51ff53da43f6972d0700602c1d4c475c8f2189c616ab58482e6c2
Stable URL of this page
https://metraipolis.com/documento/dc_5d62113eda2d

How to cite

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study — Europe PMC PMID:42118670 — Europe PMC (en), https://europepmc.org/article/MED/42118670 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5d62113eda2d (Metraipolis archive dc_5d62113eda2d, sha256 d772420c84f51ff53da43f6972d0700602c1d4c475c8f2189c616ab58482e6c2)
BibTeX
@misc{dc5d62113eda2d,
  title = {Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study — Europe PMC PMID:42118670},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42118670},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5d62113eda2d; sha256 d772420c84f51ff53da43f6972d0700602c1d4c475c8f2189c616ab58482e6c2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42118670. Agents can read the archived copy with the MCP tool read_document.